Program
petrelintide
Also written as “Petrelintide” and “ZP8396”.
Its studies are mostly in Obesity · Overweight · Renal Insufficiency, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Zealand Pharma | 71 open or running | phase 2since Oct 25, 2024 | Oct 14, 2021 | Apr 12, 2027phase 1 · NCT07682818 |
| Hoffmann-La Roche | 44 open or running | phase 3since Sep 11, 2026 | May 11, 2026 | Nov 12, 2027phase 2 · NCT07589686 |
- Named in Hoffmann-La Roche’s own pipeline as
RG6849 petrelintide (Zealand)
, phase 3, as of Oct 22, 2026 (source).
Also a collaborator on its studies: parexel, icon-clinical-research and icon-plc.
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- Co-developmentRoche develops it with Zealand Pharma, together in the US and Europe; Roche alone elsewhere.Announced Mar 12, 2025 · Source: Roche, Mar 12, 2025
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 14, 2021First study: phase 1 study in OverweightNew to Zealand PharmaZealand Pharma · NCT05096598 · 64 enrolled · Germany
- Oct 28, 2022Phase 1 study in OverweightZealand Pharma · NCT05613387 · 68 enrolled · Germany
- Oct 25, 2024Phase 2 study in ObesityZealand Pharma · NCT06662539 · 493 enrolled · United States, Poland, Romania
- Apr 11, 2025Phase 2 study in OverweightZealand Pharma · NCT06926842 · 221 enrolled · United States
- Jul 10, 2025Phase 1 study in Renal InsufficiencyZealand Pharma · NCT07076030 · 39 enrolled · Germany
- Dec 11, 2025Phase 1 study in ObesityZealand Pharma · NCT07338214 · 48 enrolled · Germany
- May 11, 2026Hoffmann-La Roche's first study: phase 2 study in ObesityNew to Hoffmann-La RocheHoffmann-La Roche · NCT07589686 · 486 planned
- Jun 26, 2026Phase 1 study in Impaired Hepatic FunctionZealand Pharma · NCT07682818 · 36 planned · Poland, Slovakia
- Sep 11, 20263 phase 3 studies in ObesityPhase 3 reachedHoffmann-La Roche · NCT07843498, NCT07843485, NCT07843472
Ahead
- Apr 12, 2027Primary completion: phase 1 study in Impaired Hepatic FunctionZealand Pharma · NCT07682818
- Nov 12, 2027Primary completion: phase 2 study in ObesityHoffmann-La Roche · NCT07589686
- Oct 20, 2028Primary completion: phase 3 study in ObesityHoffmann-La Roche · NCT07843485
- Dec 21, 2028Primary completion: phase 3 study in ObesityHoffmann-La Roche · NCT07843498
TargetBeta
“Petrelintide is a long-acting amylin analog in development for weight management.”study text, by rule · the study
Other programs on CALCR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cagrilintide | Novo Nordisk | phase 3 | 50 |
| zenagamtide | Novo Nordisk | phase 3 | 35 |
| ABBV-295 | AbbVie | phase 2 | 5 |
| PF-08653945 | Pfizer | phase 2 | 2 |
| GUB014295 | AbbVie | phase 1 | 1 |
| CagriSema A | Novo Nordisk | phase 1 | 1 |
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07843472Obesity · United States, Taiwan, United Kingdom | 3 | Recruiting | Hoffmann-La Roche | Jul 28, 2030 | 2,500 |
| NCT07843498Obesity · United States | 3 | Recruiting | Hoffmann-La Roche | Dec 21, 2028 | 3,900 |
| NCT07843485Obesity · United States | 3 | Recruiting | Hoffmann-La Roche | Oct 20, 2028 | 600 |
| NCT07682818Impaired Hepatic Function · Poland, Slovakia | 1 | Recruiting | Zealand Pharma | Apr 12, 2027 | 36 |
| NCT07589686Obesity | 2 | Not yet recruiting | Hoffmann-La Roche | Nov 12, 2027 | 486 |
| NCT07338214Obesity · Germany | 1 | Completed | Zealand Pharma | Mar 31, 2026 | 48 |
| NCT07076030Renal Insufficiency · Germany | 1 | Completed | Zealand Pharma | Nov 25, 2025 | 39 |
| NCT06926842Overweight · United States | 2 | Completed | Zealand Pharma | Aug 13, 2026 | 221 |
| NCT06662539Obesity · United States, Poland, Romania | 2 | Completed | Zealand Pharma | Sep 30, 2025 | 493 |
| NCT05613387Overweight · Germany | 1 | Completed | Zealand Pharma | Jun 13, 2024 | 68 |
| NCT05096598Overweight · Germany | 1 | Completed | Zealand Pharma | Jan 12, 2023 | 64 |
How it is read
Names in the registry
- “Petrelintide”, 9 entries
- “ZP8396”, 2 entries
Conditions, from the studies’ own filings
- Obesity, 7 studies
- Overweight, 2 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.